×
BioAge Labs Net Cash Flow 2024-2025 | BIOA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
BioAge Labs net cash flow from 2024 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
View More
BioAge Labs Net Cash Flow 2024-2025 | BIOA
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
BioAge Labs net cash flow from 2024 to 2025. Net cash flow can be defined as the total change in cash for the company over the given period.
Related Stocks
Company Name
Market
Cap
AstraZeneca (AZN)
$247.1B
Amgen (AMGN)
$155.3B
Gilead Sciences (GILD)
$141.6B
Vertex Pharmaceuticals (VRTX)
$99.7B
Bristol Myers Squibb (BMY)
$96B
GSK (GSK)
$80.7B
CSL (CSLLY)
$67.1B
Regeneron Pharmaceuticals (REGN)
$60.7B
Alnylam Pharmaceuticals (ALNY)
$58.2B
Argenex SE (ARGX)
$41.5B
Insmed (INSM)
$27.1B
BioNTech SE (BNTX)
$25.3B
Royalty Pharma (RPRX)
$21B
Biogen (BIIB)
$20B
Incyte (INCY)
$16.6B
Genmab (GNMSF)
$16.2B
Genmab (GMAB)
$15.6B
Illumina (ILMN)
$15.3B
Ascendis Pharma (ASND)
$11.7B
BioMarin Pharmaceutical (BMRN)
$11.2B
Swedish Orphan Biovitrum (BIOVF)
$10.9B
QIAGEN (QGEN)
$10.9B
Exelixis (EXEL)
$10.2B
Moderna (MRNA)
$9.9B
Verona Pharma American Depositary Share (VRNA)
$9.1B
Bio-Techne Corp (TECH)
$8.9B
Exact Sciences (EXAS)
$8.6B
Halozyme Therapeutics (HALO)
$8.4B
Blueprint Medicines (BPMC)
$8.3B
Roivant Sciences (ROIV)
$7.9B